Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Efficacy and Safety of PD-1 Inhibitor, Azacitidine and Low-dose DLI in AML Relapse After Allogeneic Hematopoietic Stem Cell Transplantation

NCT05772273 is registered in ClinicalTrials.gov with The First Affiliated Hospital of Soochow University as lead sponsor.

NCT NCT05772273
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05772273 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Efficacy and Safety of PD-1 Inhibitor, Azacitidine and Low-dose DLI in AML Relapse After Allogeneic Hematopoietic Stem Cell Transplantation
Lead sponsor
The First Affiliated Hospital of Soochow University
Phase
Not applicable
Overall status
Recruiting
Start date
March 15, 2023
Completion date
December 31, 2027
Enrollment
43 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

acute myeloid leukemia